|
|
Gerbu Adjuvant |
|
Vaxjo ID |
51 |
|
Vaccine Adjuvant Name |
Gerbu Adjuvant |
|
Adjuvant VO ID |
VO_0001293
|
|
Description |
The Gerbu Adjuvants®(GERBU Biochemicals GmbH, Am Kirchwald 6, 69251 Gaiberg, Germany) are a group of adjuvants all based on the use of the immunomodulator N-acetyl-glucosaminyl-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP1), a soluble glycopeptide from the cell wall of Lactobacillus bulgaricus. All Gerbu adjuvants also contain cimetidine as an immune enhancer, and most contain saponin, another immunomodulating compound. A specialized Gerbu adjuvant for mouse monoclonal immunization (Gerbu Adjuvant MM®) contains a poly(adenylic).poly(uridylic) acid heteroduplex (poly A:U) and theophylline, in addition to the GMDP and cimetidine. Gerbu adjuvants are aqueous adjuvants with suspended solid ultrafilterable particles composed of a paraffin mixture that contains dimethyldi(stearoylhydroxyethyl)ammonium chloride (Esterquat 1). Other components include mannide monooleate, glycerol, L-proline, and ciprofloxacin (Stills, 2005). |
|
Stage of Development |
Clinical Trial |
|
Components |
Mixture of: i) N-Acetylglucosaminyl-(Pl-4)-N-acetylmuramyl-L-alanyl-D-glutamine (GMDP), ii) Dirnethyl dioctadecylammonium. chloride (DDA), iii) Zinc L-proline salt complex (ZnPro-8) (Vogel and Powell, 1995). |
|
Preparation |
The preparation is sterile and suitable for injection after reconstitution. It is contained in 5 mL glass vials with stoppers of butyl rubber. Once reconstituted, the storage must be in the frozen state to prevent microbial growth or contamination (Vogel and Powell, 1995). |
|
Function |
Therapeutic vaccination studies in sheep and avians with Gerbu and other adjuvants have shown Gerbu to be effective for immunization and protection (Stills, 2005). |
|
Safety |
All components are extensively tested for oral and parenteral toxicity and found to be nontoxic in doses well above those recommended for immunization. Zinc and L-proline are widely used in infusions for a variety of human uses in doses larger as used in this adjuvant formula (Stills, 2005). |
| Related Vaccine(s) |
|
| References |
Stills, 2005: Stills HF Jr. Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR journal / National Research Council, Institute of Laboratory Animal Resources. 2005; 46(3); 280-293. [PubMed: 15953835].
Vogel and Powell, 1995: Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharmaceutical biotechnology. 1995; 6; 141-228. [PubMed: 7551218].
|
|
